Breaking Finance News

Syneron Medical Ltd. (NASDAQ:ELOS) price target bumped up to $8.00, issued a report today by Zacks Investment Research

Reporting a possible upside of 0.12%, Zacks Investment Research bumped up the price target of Syneron Medical Ltd. (NASDAQ:ELOS) to $8.00

Showing a price of $7.14, Syneron Medical Ltd. (NASDAQ:ELOS) traded 1.37% higher on the day. With the last close up 4.46% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. The company has recorded a 50-day average of $6.86 and a two hundred day average of $7.06. Volume of trade was down over the average, with 99,306 shares of ELOS changing hands under the typical 127,578

Recent Performance Chart

Syneron Medical Ltd. (NASDAQ:ELOS)

Syneron Medical Ltd. has 52 week low of $6.10 and a one year high of $8.47 and has a market capitalization of $0.

Brief Synopsis About Syneron Medical Ltd. (NASDAQ:ELOS)

Syneron Medical Ltd. is engaged in the manufacture, research, development, marketing and sale of equipment for the aesthetic medical industry and systems for dermatologists, plastic surgeons and other qualified practitioners. The Company designs, develops and markets aesthetic medical products based on its various technologies, including Electro-Optical Synergy (ELOS) technology, which uses the synergy between electrical energy, including radiofrequency (RF) energy, and optical energy to provide aesthetic medical treatments. Its products target an array of non-invasive aesthetic medical procedures, including hair removal, wrinkle reduction, tattoo removal, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, acne treatment, treatment of leg veins, treatment for the temporary reduction in the appearance of cellulite and thigh circumference, ablation and resurfacing of the skin, and laser-assisted lipolysis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *